An interventional study of Dried garlic powder (Garlic extract) - Allium sativum. in Hemodialysis, Endothelial Dysfunction and CKD, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Ain Shams University · Not applicable, Interventional, and Other
Chronic kidney disease (CKD) is an irreversible condition marked by reduced kidney function or structural abnormalities lasting over three months, affecting a significant portion of the global population. It leads to a cycle of complications including albuminuria, anemia, mineral bone disorders, inflammation, oxidative stress, and accumulation of uremic toxins. These factors contribute to endothelial dysfunction (ED) and elevate the risk of cardiovascular diseases (CVDs), which are the primary cause of death in end stage kidney disease (ESKD) patients, especially those undergoing hemodialysis (HD). Hemodialysis further aggravates systemic inflammation and oxidative stress, increasing levels of cytokines like IL-6, TNF-α, and CRP. Endocan, a proteoglycan secreted by endothelial cells in response to inflammation, is a promising biomarker for ED and CVD risk, with levels that correlate with CKD severity. Garlic (Allium sativum) contains bioactive compounds with proven anti-inflammatory, antioxidant, and endothelial protective effects. This trial was suggested based on a study that has reported that giving 400 mg of garlic extract twice a day for 8 weeks in peritoneal dialysis patients resulted in significant reduction in IL-6, CRP and ESR. This study aims to investigate the effect of Garlic on Endothelial dysfunction and inflammation in chronic hemodialysis patients via assessment of Endocan as an endothelial dysfunction marker and IL-6 as an inflammation marker.
3,438 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 58 is above the median of 50 across 2,436 interventional studies indexed under Inflammation.
Browse Inflammation studies →Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
It consists of 29 patients who will receive a tablet containing 300 mg dried garlic powder three times daily for 12 weeks. (Tomex® plus, ATOS Pharma, Egypt) besides the standard treatment.
Dietary Supplement: Dried garlic powder (Garlic extract) - Allium sativum.
It consists of 29 patients who will receive the standard treatment.
A tablet containing 300 mg dried garlic powder
endocan
To evaluate the impact of Garlic on endothelial dysfunction in chronic hemodialysis patients via assessment of Endocan.
Time frame: 12 weeks
interleukin-6
To evaluate the impact of Garlic on inflammation in chronic hemodialysis patients via assessment of IL-6 marker.
Time frame: 12 weeks
safety of garlic in CHD patients
To evaluate the safety of Garlic in patients on HD by monitoring any adverse effects that may occur.
Time frame: 12 weeks
(KDQOL™-36) questionnaire
To evaluate the impact of Garlic on quality of life in CHD patients
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University